Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY4256984
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intrathecal
01
Overview
LY4256984 is a new molecular entity classified as a neuroprotectant, administered intrathecally, and is being developed by Eli Lilly and Company for the treatment of amyotrophic lateral sclerosis (ALS)[1][3][5]. It is in Phase 1 clinical trials for sporadic ALS, focusing on evaluating safety, tolerability, and pharmacokinetics. The specific mechanism of action has not been disclosed as of the latest available information[5].
- Other names
- LY4256984LY-4256984LY 4256984
Beyond the preview
Go deeper on LY4256984.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY4256984.